secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-11-28T23:59:59+00:00
Accession:  0001213900-25-116103
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

ENDRA Life Sciences CTO Resigns, Enters Consulting Agreement; CFO Services Formalized
--------------------------------------------------------------------------------

- Michael Thornton resigned as CTO effective Nov 28, 2025; entered Consulting Agreement at $150/hr (first 5 hrs/week) then $100/hr.
- Richard Jacroux continues as CFO via Impact Solve LLC; initial monthly fee $8,650 increasing to $10,800 from Jan 1, 2026.
- Thornton's outstanding Options and RSUs remain outstanding and continue to vest during the consulting term.
- Impact Solve Advisory Services Agreement replaces prior services agreement for CFO duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025116103/0001213900-25-116103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025116103/ea0267731-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer